Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mildred Sabo

Geriatric Medicine Stuart, FL Medical Doctor

NPI 1225001126 CMS profile 796431

900 Se Salerno Rd, Stuart, FL 34997

Open in the dashboard

General payments

$1,658

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mildred Sabo of Stuart, FL is reported in the CMS Open Payments database as having received $1,658 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $411 11
2024 General $383 14
2023 General $295 11
2022 General $13 1
2021 General $34 2
2020 General $189 5
2019 General $334 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mildred Sabo
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Mildred Sabo were reported at $411. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Mildred Sabo Geriatric Medicine median Middle half National median
2019 $334 $96 $28–$339 $163
2020 $189 $99 $28–$262 $114
2021 $34 $94 $27–$318 $132
2022 $13 $103 $34–$338 $149
2023 $295 $109 $39–$320 $160
2024 $383 $125 $36–$371 $164
2025 $411 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $413 14 payments
  2. AstraZeneca Pharmaceuticals LP $296 5 payments
  3. Otsuka America Pharmaceutical, Inc. $253 3 payments
  4. Abbott Laboratories $197 3 payments
  5. Lilly USA, LLC $90 4 payments
  6. Pfizer Inc. $72 4 payments
  7. Exact Sciences Corporation $70 3 payments
  8. Insmed, Inc. $41 2 payments
  9. Amgen Inc. $33 2 payments
  10. Seqirus USA Inc $21 1 payment
  11. Other $171 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,658 51 payments
Products named General payments · program years 2019–2025
  1. Ozempic $357 11 payments
  2. FARXIGA $271 4 payments
  3. REXULTI $253 3 payments
  4. Mitra Clip system $154 1 payment
  5. Cologuard Collection Kit $70 3 payments
  6. RYBELSUS $69 4 payments
  7. PREVNAR 20 $55 3 payments
  8. KISUNLA $53 2 payments
  9. FreeStyle Libre 3 $43 2 payments
  10. COMIRNATY $43 2 payments
  11. Other $568 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,125

Median for Geriatric Medicine: 2,306

Drug cost

$159,287

Median for Geriatric Medicine: $150,713

Branded share of claims

13.9%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $39,859
Ozempic Semaglutide Brand 22 $30,261
Xarelto Rivaroxaban Brand 11 $18,335
Jardiance Empagliflozin Brand 12 $15,802
Mounjaro Tirzepatide Brand 12 $14,387
Synthroid Levothyroxine Sodium Brand 36 $3,134
Paxlovid Nirmatrelvir/Ritonavir Brand 16 $2,799
Rosuvastatin Calcium Generic 137 $2,119
Atorvastatin Calcium Generic 250 $2,116
Losartan Potassium Generic 200 $1,901

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$167,400

Of which drugs: $11,954

Medicare patients

590

Average age 80

Services billed

2,769

383 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 27%
Chronic kidney disease 26%
Atrial fibrillation 21%
Depression 21%
Diabetes 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 83 83 $6,094
Pcv20 vaccine im 90677 Office 20 20 $5,786

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $133
  • Lundbeck LLC $20
$153 — —
Ozempic
  • Novo Nordisk Inc $45
$45 22 —
KISUNLA
  • Lilly USA, LLC $39
$39 — —
RYBELSUS
  • Novo Nordisk Inc $24
$24 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record